February 15th- CML in 2026: From Disease Control to Functional Cure

CME Congresses .

February 15th- CML in 2026: From Disease Control to Functional Cure

February 9th- Dr. Hira Mian- Redefining the Treatment Landscape of Multiple Myeloma – Key Messages from the 2026 ASCO–Ontario Health Living Guideline

CME Congresses .

February 9th- Dr. Hira Mian- Redefining the Treatment Landscape of Multiple Myeloma – Key Messages from the 2026 ASCO–Ontario Health Living Guideline

February 4th- A New Step Forward in Chronic GVHD Care

CME Congresses .

February 4th- A New Step Forward in Chronic GVHD Care

February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

CME Congresses .

February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial

CME Congresses .

February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial

February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma

CME Congresses .

February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma

January 27th- Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

CME Congresses .

January 27th- Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

January 26th- From Ibrutinib to Zanubrutinib in Waldenström Macroglobulinemia: Is Switching Safe- and Does It Matter?

CME Congresses .

January 26th- From Ibrutinib to Zanubrutinib in Waldenström Macroglobulinemia: Is Switching Safe- and Does It Matter?

January 21st- Microbiota and GVHD: From Unmet Need to a New Therapeutic Paradigm

CME Congresses .

January 21st- Microbiota and GVHD: From Unmet Need to a New Therapeutic Paradigm

January 19th- Luspatercept in Lower-Risk MDS- where do we stand

CME Congresses .

January 19th- Luspatercept in Lower-Risk MDS- where do we stand